Seaside Therapeutics will proceed with late-stage trials of drug candidate STX209 for fragile X syndrome and autism spectrum disorder. The move comes after a second Phase II study showed that the treatment significantly improved symptoms of autism spectrum disorder in patients ages 6 to 17. The first trial was a placebo-controlled study of fragile X syndrome patients.

Related Summaries